Genetic trait may heighten anaphylaxis risk for people with SM
A genetic trait that increases risk of anaphylaxis is higher in people with SM. Identifying the trait early could mean better treatment.
A genetic trait that increases risk of anaphylaxis is higher in people with SM. Identifying the trait early could mean better treatment.
The targeted therapy drug gemtuzumab ozogamicin successfully treated a young boy with SM-AHN who did not respond to conventional therapies.
As fire ants spread to more areas, people with SM face a greater risk of severe allergic reactions from fire ant stings.
Avapritinib treatment improves survival outcomes and symptom management in patients with SM, its maker reported.